<DOC>
	<DOCNO>NCT02786511</DOCNO>
	<brief_summary>This multi-center , non-randomized , open label , longterm safety efficacy follow-up study subject treat bb2121 Phase 1 clinical parent study , evaluate safety efficacy bb2121 subject relapse refractory B cell maturation antigen ( BCMA ) -expressing multiple myeloma . bb2121 define autologous T lymphocyte ( T cell ) transduce ex vivo anti-BCMA02 CAR lentiviral vector encode chimeric antigen receptor ( CAR ) target human BCMA suspend cryopreservative solution . bb2121 administer subject 1 time ( retreat retreatment criterion meet ) parent clinical study . No investigational treatment administer study . After complete parent study , eligible subject follow 15 year last bb2121 infusion parent study .</brief_summary>
	<brief_title>Longterm Follow-up Subjects Treated With bb2121</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<criteria>Provision write informed consent study subject Were administer bb2121 parent clinical study Able comply study requirement Subject disease progression AND subject undetectable VCN ( &lt; 0.0003 vector copy per diploid genome ) peripheral blood cell 2 consecutive measurement least 1 month apart , least 12 month drug product infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>